M&As this week: Shanghai ChemPartner Co, Cell Medica, BBI Group Holding

22nd June 2017 (Last Updated June 22nd, 2017 18:30)

ShangPharma Corporation's contract research subsidiary Shanghai ChemPartner Co Ltd is set to merge with Quantum Hi-Tech (China) Biological Co Ltd.

ShangPharma Corporation's contract research subsidiary Shanghai ChemPartner Co Ltd is set to merge with Quantum Hi-Tech (China) Biological Co Ltd.. 

A reverse merger agreement has been reached between the two companies, which will add more value for shareholders.

Both companies involved in the merger are based in China.

Cell Medica Ltd has completed the acquisition of Catapult Therapy TCR Limited from Cell Therapy Catapult Ltd.

The target company develops cell therapy for the treatment of acute myeloid leukaemia. Cell Medica is a developer of cellular immunotherapy for treating cancer, and expects the acquisition to help create an effective treatment for patients with solid tumours.

All companies involved in the transaction are based in the UK.

"Upon closure of the merger, security holders of Innovate and Monster Digital are expected to hold approximately 90.90% and 9.10% respectively of the combined company."

BBI Group Holding Ltd has reached an agreement to acquire Maine Biotechnology Services Inc with the aim of expanding its portfolio.

Based in the UK, the acquiring company provides products and services through its businesses to the diagnostic, healthcare, research, defence, food and cosmetics industries. The target company is a custom antibody discovery service provider based in the US. 

US-based consumer electronics designer and developer Monster Digital Inc has signed a non-binding letter of intent (LoI) to merge with Innovate Biopharmaceuticals Inc in a reverse merger transaction.

Upon closure of the merger, security holders of Innovate and Monster Digital are expected to hold approximately 90.90% and 9.10% respectively of the combined company. 

Also based in the US, Innovative Biopharmaceuticals develops gastroenterology drugs.